300765 石药创新
已收盘 09-16 15:00:00
资讯
新帖
简况
研报掘金丨东吴证券:维持石药创新“买入”评级,创新管线进入密集收获期
格隆汇 · 09-16 14:49
研报掘金丨东吴证券:维持石药创新“买入”评级,创新管线进入密集收获期
石药创新:SYS6010再获突破性治疗认定 III期临床试验正在开展
同花顺 · 09-15 19:08
石药创新:SYS6010再获突破性治疗认定 III期临床试验正在开展
石药创新:SYS6010纳入突破性治疗品种名单
格隆汇 · 09-15 16:34
石药创新:SYS6010纳入突破性治疗品种名单
石药创新:控股子公司SYS6010肺癌研究成果公布
同花顺 · 09-14 16:22
石药创新:控股子公司SYS6010肺癌研究成果公布
石药创新:关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报业绩说明会的公告
同花顺 · 09-11
石药创新:关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报业绩说明会的公告
9月9日石药创新跌7.58%,工银前沿医疗股票A基金重仓该股
证券之星 · 09-09
9月9日石药创新跌7.58%,工银前沿医疗股票A基金重仓该股
燕文物流、爱士惟等公司香港IPO获中国证监会接收材料
同花顺 · 09-04
燕文物流、爱士惟等公司香港IPO获中国证监会接收材料
石药创新(300765)披露控股子公司SYS6010纳入突破性治疗品种名单用于治疗复发或转移性头颈鳞癌患者,9月2日股价下跌0.09%
证券之星 · 09-02
石药创新(300765)披露控股子公司SYS6010纳入突破性治疗品种名单用于治疗复发或转移性头颈鳞癌患者,9月2日股价下跌0.09%
石药创新(300765.SZ)子公司SYS6010纳入突破性治疗品种名单
智通财经 · 09-01
石药创新(300765.SZ)子公司SYS6010纳入突破性治疗品种名单
股市必读:石药创新(300765)8月28日董秘有最新回复
证券之星 · 08-31
股市必读:石药创新(300765)8月28日董秘有最新回复
石药创新:公司暂未布局流感相关药品
证券之星 · 08-28
石药创新:公司暂未布局流感相关药品
石药创新:该产品于2025年9月取得临床试验批准通知书
证券之星 · 08-28
石药创新:该产品于2025年9月取得临床试验批准通知书
石药创新:巨石生物的单抗大品种生产线、ADC 新产品商业化生产线项目目前尚处于建设期
证券之星 · 08-28
石药创新:巨石生物的单抗大品种生产线、ADC 新产品商业化生产线项目目前尚处于建设期
8月28日石药创新跌5.43%,工银前沿医疗股票A基金重仓该股
证券之星 · 08-28
8月28日石药创新跌5.43%,工银前沿医疗股票A基金重仓该股
石药创新最新公告:控股子公司药物获美国FDA快速通道资格
证券之星 · 08-26
石药创新最新公告:控股子公司药物获美国FDA快速通道资格
8月24日石药创新跌7.67%,工银前沿医疗股票A基金重仓该股
证券之星 · 08-24
8月24日石药创新跌7.67%,工银前沿医疗股票A基金重仓该股
8月20日石药创新涨20.00%,工银前沿医疗股票A基金重仓该股
证券之星 · 08-20
8月20日石药创新涨20.00%,工银前沿医疗股票A基金重仓该股
石药创新(300765.SZ)控股子公司SYS6090启动Ib/II期临床试验
智通财经 · 08-19
石药创新(300765.SZ)控股子公司SYS6090启动Ib/II期临床试验
股市必读:石药创新新发布《2026年半年度报告摘要》
证券之星 · 08-19
股市必读:石药创新新发布《2026年半年度报告摘要》
石药创新:截至2026年8月10日股东数为31,534户
证券之星 · 08-18
石药创新:截至2026年8月10日股东数为31,534户
公司概况
公司名称:
石药创新制药股份有限公司
所属行业:
食品制造业
上市日期:
2019-03-22
主营业务:
石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是抗体药物、ADC药物、mRNA疫苗、药品、咖啡因、阿卡波糖、无水葡萄糖原料及果维康维生素C含片、维生素B族含片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一,已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。
发行价格:
24.47
{"stockData":{"symbol":"300765","market":"SZ","secType":"STK","nameCN":"石药创新","latestPrice":43.16,"timestamp":1789542237000,"preClose":43.16,"halted":0,"volume":15936031,"delay":0,"changeRate":0,"floatShares":1405000000,"shares":1405000000,"eps":0.7282,"marketStatus":"已收盘","change":0,"latestTime":"09-16 15:00:00","open":43.58,"high":44.5,"low":42.83,"amount":692000000,"amplitude":0.0387,"askPrice":43.16,"askSize":204,"bidPrice":43.15,"bidSize":25,"shortable":0,"etf":0,"ttmEps":0.7282,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":5,"adr":0,"adjPreClose":43.16,"symbolType":"stock","openAndCloseTimeList":[[1789522200000,1789529400000],[1789534800000,1789542000000]],"highLimit":47.48,"lowLimit":38.84,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1404592944,"isCdr":false,"pbRate":15.4,"roa":"--","peRate":59.269431,"roe":"38.2%","epsLYR":-0.1731,"committee":-0.619048,"marketValue":60622000000,"turnoverRate":0.0113,"status":2,"floatMarketCap":60622000000},"requestUrl":"/m/hq/s/300765/wiki","defaultTab":"wiki","newsList":[{"id":"2667608835","title":"研报掘金丨东吴证券:维持石药创新“买入”评级,创新管线进入密集收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608835","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667608835?lang=zh_cn&edition=full","pubTime":"2026-09-16 14:49","pubTimestamp":1789541344,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0226","BK0188","601555","BK0276","300765","BK0028","BK0183","BK0012","BK0009"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667264193","title":"石药创新:SYS6010再获突破性治疗认定 III期临床试验正在开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2667264193","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667264193?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:08","pubTimestamp":1789470480,"startTime":"0","endTime":"0","summary":"中证智能财讯石药创新(300765)9月15日晚间公告,公司控股子公司石药集团巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单,拟定适应症为免疫及含 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260915/c679932866.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260915/c679932866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["PSYK","MDTX","BMED","IBBJ","IBBQ","300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667610909","title":"石药创新:SYS6010纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2667610909","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667610909?lang=zh_cn&edition=full","pubTime":"2026-09-15 16:34","pubTimestamp":1789461242,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667628659","title":"石药创新:控股子公司SYS6010肺癌研究成果公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2667628659","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667628659?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:22","pubTimestamp":1789374120,"startTime":"0","endTime":"0","summary":"9月14日,石药创新(300765.SZ)公告称,公司控股子公司巨石生物在2026年世界肺癌大会上,以口头报告形式公布SYS6010联合恩朗苏拜单抗I/II期临床研究数据。SYS6010为巨石生物自主研发的EGFR靶 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260914/c679879866.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260914/c679879866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666522033","title":"石药创新:关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报业绩说明会的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2666522033","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666522033?lang=zh_cn&edition=full","pubTime":"2026-09-11 21:01","pubTimestamp":1789131660,"startTime":"0","endTime":"0","summary":" 证券日报网讯9月11日,石药创新发布公告称,公司将参加“2026年度河北辖区上市公司投资者网上集体接待日暨2026年半年报业绩说明会活动”,活动时间为2026年9月16日 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260911/c679842541.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260911/c679842541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666058631","title":"9月9日石药创新跌7.58%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666058631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666058631?lang=zh_cn&edition=full","pubTime":"2026-09-09 16:39","pubTimestamp":1788943143,"startTime":"0","endTime":"0","summary":"证券之星消息,9月9日石药创新跌7.58%,收盘报41.72元,换手率2.02%,成交量28.37万手,成交额12.42亿元。重仓石药创新的前十大公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900027793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664539339","title":"燕文物流、爱士惟等公司香港IPO获中国证监会接收材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2664539339","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664539339?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:04","pubTimestamp":1788519840,"startTime":"0","endTime":"0","summary":"9月4日,中国证监会发布《境内企业境外发行证券和上市备案情况表(首次公开发行及全流通)(截至2026年9月4日)》。其中,燕文物流、爱士惟、智租物联、灵卡科技、石药创新(300765.SZ)、清明上 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260904/c679615949.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260904/c679615949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0012","BK0214","BK0224","BK0028","601126","BK0226","688403","300765","BK0130","BK0078","BK0069","BK0158","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664890915","title":"石药创新(300765)披露控股子公司SYS6010纳入突破性治疗品种名单用于治疗复发或转移性头颈鳞癌患者,9月2日股价下跌0.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664890915","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664890915?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:27","pubTimestamp":1788341259,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘,石药创新报收于44.5元,较前一交易日下跌0.09%,最新总市值为625.04亿元。近日,石药创新制药股份有限公司发布公告称,其控股子公司巨石生物开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单,适用于经免疫和含铂化疗治疗失败的复发或转移性头颈鳞癌患者。SYS6010是一款靶向EGFR的抗体偶联药物,目前关键III期临床试验正在进行中。此前该药物已获两项突破性治疗认定,分别针对非小细胞肺癌和食管鳞癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200030925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664373388","title":"石药创新(300765.SZ)子公司SYS6010纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2664373388","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664373388?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:14","pubTimestamp":1788254043,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药创新(300765.SZ)发布公告,公司控股子公司石药集团巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心(简称“药审中心”)纳入突破性治疗品种名单。该药品拟定适应症(或功能主治)为:经免疫和含铂化疗治疗失败的复发或转移性头颈鳞癌(R/M HNSCC)患者。公告显示,此前,SYS6010已获得药审中心授予的2项突破性治疗认定(不含此次),拟定适应症分别为:单药用于经EGFR-TKI和含铂化疗治疗失败的EGFR突变阳性晚期非小细胞肺癌(NSCLC);既往一线接受含铂化疗和免疫检查点抑制剂(ICI)治疗后失败的不可切除的局部晚期或转移性食管鳞癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药创新(300765.SZ)子公司SYS6010纳入突破性治疗品种名单","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663569042","title":"股市必读:石药创新(300765)8月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2663569042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663569042?lang=zh_cn&edition=full","pubTime":"2026-08-31 01:10","pubTimestamp":1788109817,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,石药创新报收于44.4元,下跌5.43%,换手率1.86%,成交量26.12万手,成交额11.86亿元。投资者: 请问贵司的仑卡奈单抗注射液目前临床进程,以及上市计划董秘: 您好,感谢您对公司的关注,该产品于2025 年 9 月取得临床试验批准通知书,后续进展请留意公司公告,谢谢。董秘: 您好,感谢您对公司的关注,截至2026年8月20日,公司合并普通账户和融资融券信用账户股东数为33,821户,谢谢!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100000563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662063660","title":"石药创新:公司暂未布局流感相关药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2662063660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662063660?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:09","pubTimestamp":1787908147,"startTime":"0","endTime":"0","summary":"证券之星消息,石药创新(300765)08月28日在投资者关系平台上答复投资者关心的问题。投资者提问:贵司研发的创新药品或疫苗、目前有针对流感领域的药品吗?石药创新回复:您好,感谢您对公司的关注,公司暂未布局流感相关药品,谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800039260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662633080","title":"石药创新:该产品于2025年9月取得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2662633080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662633080?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:00","pubTimestamp":1787907627,"startTime":"0","endTime":"0","summary":"证券之星消息,石药创新(300765)08月28日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵司的仑卡奈单抗注射液目前临床进程,以及上市计划石药创新回复:您好,感谢您对公司的关注,该产品于2025 年 9 月取得临床试验批准通知书,后续进展请留意公司公告,谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800038955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662063316","title":"石药创新:巨石生物的单抗大品种生产线、ADC 新产品商业化生产线项目目前尚处于建设期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662063316","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662063316?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:00","pubTimestamp":1787907626,"startTime":"0","endTime":"0","summary":"证券之星消息,石药创新(300765)08月28日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,请问巨石生物单抗和ADC两条生产线建设完成了吗?什么时候可以投入运营?谢谢石药创新回复:您好,感谢您对公司的关注,巨石生物的单抗大品种生产线、ADC 新产品商业化生产线项目目前尚处于建设期,谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800038954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662068340","title":"8月28日石药创新跌5.43%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662068340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662068340?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:41","pubTimestamp":1787906494,"startTime":"0","endTime":"0","summary":"证券之星消息,8月28日石药创新跌5.43%,收盘报44.4元,换手率1.86%,成交量26.12万手,成交额11.86亿元。重仓石药创新的前十大公募基金请见下表:该股最近90天内共有3家机构给出评级,买入评级3家。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800038474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","159891","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662879146","title":"石药创新最新公告:控股子公司药物获美国FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2662879146","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662879146?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:17","pubTimestamp":1787735872,"startTime":"0","endTime":"0","summary":"石药创新(300765.SZ)公告称,公司控股子公司巨石生物研发的首创PD-1/IL-15双特异性融合蛋白SYS6090(JMT108)获美国FDA授予快速通道资格,用于治疗既往经标准系统性治疗后出现疾病进展的微卫星稳定或错配修复功能完整型转移性结直肠癌患者。该资格有助于加快药物开发与审批进程,但最终获批上市仍存在不确定性。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600038205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661224335","title":"8月24日石药创新跌7.67%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661224335","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661224335?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:41","pubTimestamp":1787560882,"startTime":"0","endTime":"0","summary":"证券之星消息,8月24日石药创新跌7.67%,收盘报45.24元,换手率3.35%,成交量47.05万手,成交额21.55亿元。重仓石药创新的前十大公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400022137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660027674","title":"8月20日石药创新涨20.00%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660027674","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660027674?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:43","pubTimestamp":1787215426,"startTime":"0","endTime":"0","summary":"证券之星消息,8月20日石药创新涨20.00%创60日新高,收盘报51.78元,换手率4.59%,成交量64.52万手,成交额32.28亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000029030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660436514","title":"石药创新(300765.SZ)控股子公司SYS6090启动Ib/II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2660436514","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660436514?lang=zh_cn&edition=full","pubTime":"2026-08-19 15:59","pubTimestamp":1787126378,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药创新 发布公告,公司控股子公司石药集团巨石生物制药有限公司已于近日启动一项评价SYS6090注射液联合治疗在肝细胞癌参与者中的安全性、耐受性及有效性的Ib/Ⅱ期临床试验。目前,SYS6090-007研究的参与者招募和筛选工作正在积极推进中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481899.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765","MDTX","IBBQ","BK0226","PSYK","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660499531","title":"股市必读:石药创新新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660499531","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660499531?lang=zh_cn&edition=full","pubTime":"2026-08-19 00:55","pubTimestamp":1787072112,"startTime":"0","endTime":"0","summary":"公司公告汇总:2026年半年度报告显示营业收入同比增长208.72%,归母净利润由上年同期亏损274.61万元转为盈利12.61亿元。第七届董事会第四次会议决议公告2026年8月14日召开第七届董事会第四次会议,审议通过《2026年半年度报告》及其摘要、《2026年半年度募集资金存放、管理与实际使用情况的专项报告》、增加2026年度日常关联交易预计额度、增加自有资金进行现金管理额度等议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660466660","title":"石药创新:截至2026年8月10日股东数为31,534户","url":"https://stock-news.laohu8.com/highlight/detail?id=2660466660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660466660?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:51","pubTimestamp":1787046673,"startTime":"0","endTime":"0","summary":"证券之星消息,石药创新(300765)08月18日在投资者关系平台上答复投资者关心的问题。投资者提问:您好!请问截至8月10日公司股东人数是多少,谢谢石药创新回复:您好,感谢您对公司的关注,截至2026年8月10日,公司合并普通账户和融资融券信用账户股东数为31,534户,谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800031885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789600118163,"stockEarnings":[{"period":"1week","weight":0.0345},{"period":"1month","weight":-0.0288},{"period":"3month","weight":0.8021},{"period":"6month","weight":0.431},{"period":"1year","weight":-0.1233},{"period":"ytd","weight":0.1966}],"compareEarnings":[{"period":"1week","weight":-0.0152},{"period":"1month","weight":-0.0229},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0165},{"period":"1year","weight":0.0077},{"period":"ytd","weight":-0.0195}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石药创新制药股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"33821人(较上一季度增加7.25%)","perCapita":"41530股","listingDate":"2019-03-22","address":"河北省石家庄市栾城区张举路62号","registeredCapital":"140459万元","survey":" 石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是抗体药物、ADC药物、mRNA疫苗、药品、咖啡因、阿卡波糖、无水葡萄糖原料及果维康维生素C含片、维生素B族含片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一,已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。","listedPrice":24.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药创新,300765,石药创新股票,石药创新股票老虎,石药创新股票老虎国际,石药创新行情,石药创新股票行情,石药创新股价,石药创新股市,石药创新股票价格,石药创新股票交易,石药创新股票购买,石药创新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}